R1 Launches Phare Audit, the AI-Native Solution to Capture Full Reimbursement, Reduce Revenue Leakage and Improve Quality Phare Audit Uses Proprietary Agentic AI to Maximize Earned Reimbursement, Enhancing R1's Industry-Leading DRG-V with Full Auditability GlobeNewswire January 08, 2026 CHICAGO, Jan. 08, 2026 (GLOBE NEWSWIRE) — R1 (“R1” or the “Company”), the leader in healthcare revenue […]

Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials GlobeNewswire January 08, 2026 FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026 HREC Approval Received for Next-Generation Bispecific NAV-242 to Initiate First-in-Human Phase 1 Program with Ph1a

Satellogic Announces Seven-Figure Monitoring Agreement with Strategic Customer Agreement Supports Continuous, High-Revisit Monitoring at Scale GlobeNewswire January 08, 2026 NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (“Satellogic”) (NASDAQ: SATL), a leader in high-performance Earth Observation (“EO”) platforms that deliver unique sovereign solutions and AI-first monitoring, today announced a seven-figure agreement with a

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights GlobeNewswire January 08, 2026 Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-109,

G Squared and Nasdaq Private Market Announce Strategic Partnership to Power Liquidity for Private Company Employees and Shareholders New collaboration combines G Squared's dedicated secondary capital with NPM's liquidity execution platform to help private companies design and deliver secondary liquidity when they need it most GlobeNewswire January 08, 2026 NEW YORK, Jan. 08, 2026 (GLOBE

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia GlobeNewswire January 08, 2026 Findings reinforce brilaroxazine's treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also

CytomX Therapeutics Announces Business Update and Company Milestones for 2026 GlobeNewswire January 08, 2026 – CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 – – Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027

RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026 GlobeNewswire January 08, 2026 MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) — RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today provided a corporate update and announced its strategic priorities for 2026. “We had a remarkable

CareCloud Brings Wellsoft to Urgent Care with Affinity Deal, Targeting a Larger Nationwide Market Opportunity GlobeNewswire January 08, 2026 SOMERSET, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and AI-powered solutions, today announced that Affinity Urgent Care (“Affinity”), a multi-site provider of

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 GlobeNewswire January 08, 2026 New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: